Dopamine agonist and tamoxifen combination therapy for a prolactin-secreting pituitary tumor resistant to dopamine agonist monotherapy: Case report and review
نویسندگان
چکیده
منابع مشابه
Dopamine Agonist Therapy in Advanced Parkinson’s Disease
“Parkinson’s disease (PD) doesn’t kill you, it takes your life away.” This is a disturbing quotation by the English Parkinson Lay Organisation. There is, however, no other neurodegenerative disease which responds better to treatment than PD. Treatment of advanced PD is located between these poles (Figure 1). Most national guidelines and papers on the treatment of PD recommended that early phase...
متن کاملTemozolomide therapy for resistant prolactin-secreting pituitary adenomas and carcinomas: a systematic review.
Pituitary tumors represent 10-15% of all intracranial tumors; of these, prolactinomas account for 40-50% of cases. Prolactinomas usually respond well to dopamine agonists (DA) as first-line therapy. However, treatment resistance remains a concern. Temozolomide (TMZ) is an oral alkylating agent that has shown promise in treating aggressive pituitary adenomas and carcinomas that are resistant to ...
متن کاملSide effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology
Dopamine agonists (DA) are therapeutic agents that are commonly used in the treatment of Parkinson's disease (PD). They can reduce undesired motor fluctuations and delay the administration of levodopa therapy. However, this drug family is associated with specific side effects that can significantly diminish the quality of life among PD patients. Some of them impose significant risks for individ...
متن کاملOutcomes of assisted reproduction treatment after dopamine agonist -cabergoline- for prevention of ovarian hyper stimulation syndrome
Background: Release of vascular endothelial growth factor (VEGF) by ovaries in response to HCG administration is one of the main mechanisms of ovarian hyper stimulation syndrome. Since Dopamine/dopamine receptor2 (Dp-r2) pathway activity -mediated by VEGF/ Vascular endothelial growth factor receptor 2 (VEGFR-2) signaling-, is associated with angiogenic events, dopamine agonists were used for th...
متن کاملDopamine agonist withdrawal syndrome in Parkinson's disease.
OBJECTIVES To report and characterize a dopamine agonist (DA) withdrawal syndrome (DAWS) in Parkinson disease. DESIGN Retrospective cohort study. SETTING Outpatient tertiary movement disorders clinic. Patients A cohort of 93 nondemented patients with Parkinson disease enrolled in a prospective study of nonmotor and motor disease manifestations. Main Outcome Measure The presence of DAWS, def...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Interdisciplinary Neurosurgery
سال: 2020
ISSN: 2214-7519
DOI: 10.1016/j.inat.2020.100777